¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"ovulation inhibitor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼Ò¾ïÁ¦Á¦
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦
  • corrosion inhibitor
    ºÎ½Ä¾ïÁ¦Á¦
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • inhibitor
    1. ¾ïÁ¦Á¦ 2. ¾ïÁ¦ÀÎÀÚ
  • mitotic inhibitor
    À¯»çºÐ¿­¾ïÁ¦Á¦
  • metabolic inhibitor
    ´ë»ç¾ïÁ¦Á¦
  • oocyte maturation inhibitor
    ³­ÀÚ¼º¼÷¾ïÁ¦ÀÎÀÚ
  • polymerization inhibitor
    ÁßÇÕ¾ïÁ¦Á¦
  • protease inhibitor
    ´Ü¹éÁúºÐÇØÈ¿¼Ò¾ïÁ¦Á¦
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëȥʾïÁ¦Á¦
  • specific inhibitor
    ƯÀ̾ïÁ¦Á¦
  • specific serotonin reuptake inhibitor
    ƯÀ̼¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • selective serotonin reabsorption inhibitor
    ¼±Åü¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦
  • corrosion inhibitor
    ºÎ½Ä¾ïÁ¦Á¦
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor substance
    ¾ïÁ¦¹°Áú
  • metabolic inhibitor
    ´ë»ç¾ïÁ¦Á¦
  • mitotic inhibitor
    Çٺп­¾ïÁ¦Á¦
  • oocyte maturation inhibitor
    ³­ÀÚ¼º¼÷¾ïÁ¦ÀÎÀÚ
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëȥʾïÁ¦Á¦
  • polymerization inhibitor
    ÁßÇÕ¾ïÁ¦Á¦
  • protease inhibitor
    ´Ü¹éºÐÇØÈ¿¼Ò¾ïÁ¦Á¦
  • specific inhibitor
    ƯÀ̾ïÁ¦Á¦
  • specific serotonin reuptake inhibitor
    ¼±ÅÃÀû¼¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitor
    ¾ïÁ¦ÀÚ
  • inhibitor polymerization
    ÁßÇÕ¾ïÁ¦Á¦.
  • inhibitor sensitive esterase
    ¾ïÁ¦¹°Áú¹ÝÀÀ¿¡½ºÅ×¶ó¾ÆÁ¦.
  • inter-alpha-trypsin inhibitor
    ÀÎÅÍ-¾ËÆÄ-Æ®¸³½Å ¾ïÁ¦Á¦
  • plasma thromboplastin inhibitor
    ÇöóÁ <Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¾ïÁ¦¹°Áú.
  • plasmin activation inhibitor
    Çö󽺹ÎȰ¼ºÈ­¾ïÁ¦Á¦(¡­üÀàõûùåäð¤ð¥)
  • protease inhibitor
    ´Ü¹éÁúºÐÇØÈ¿¼Ò¾ïÁ¦Á¦
  • reductase, 5-alpha-reductase inhibitor
    5a-ȯ¿øÈ¿¼Ò¾ïÁ¦Á¦(¡­ü½êªý£áÈåäð¤ð¥),5a-¸®´öÅ×À̽º¾ïÁ¦Á¦(¡­åäð¤ð¥)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reflex ovulation
    ¹Ý»ç¼º ¹è¶õ(¡­àõÛÉÕ°).
  • spontaneous ovulation
    ÀÚ¿¬¹è¶õ
  • superovular ovulation
    °ú´Ù¹è¶õ
  • uniovular ovulation
    Ȭ¹è¶õ
  • acetylcholinesterase inhibitor
    ¾Æ¼¼Æ®Äݸ°¿¡½ºÅÍ·¹À̽º<¿¡½ºÅ×¶óÁ¦> ¾ïÁ¦Á¦.
  • activated protein C inhibitor
    Ȱ¼ºÈ­´Ü¹éÁú C ¾ïÁ¦Á¦
  • angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¹°Áú<¾à>.
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
  • beta (¥â)-lactamase inhibitor
    º£Å¸¶ôŸ¸¶Á¦¾ïÁ¦Á¦
  • c inhibitor deficiency
    º¸Ã¼ ÀúÁöÀÎÀÚ °áÇÌÁõ(ÜÍô÷îÁò­ì×í­ÌÀù¹ñø)
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼ÒÀúÇØ¾à(¡­ðæúªå·), ź»êÅ»¼öÈ¿¼ÒÀú ÇØ¹°Áú, ź»êÅ»¼ö¾ïÁ¦¾à.
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼ÒÀúÇØ¾à(¡­ðæúªå·), ź»êÅ»¼öÈ¿¼ÒÀúÇØ¹°Áú
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼ÒÀúÇØ¾à(¡­ðæúªå·), ź»êÅ»¼öÈ¿¼ÒÀúÇØ¹°Áú, ź»êÅ»?
  • cell wall inhibitor
    ¼¼Æ÷º®ÇÕ¼º¾ïÁ¦Á¦
  • cholinesterase inhibitor
    Äݸ°¿¡½ºÅ×¶óÁ¦ ¾ïÁ¦Á¦
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Trojan horse inhibitor
    Æ®·ÎÀ̸ñ¸¶(ÙÊØ©) ÀúÇØÁ¦(îÁúªð¥)
  • uncompetitive inhibitor
    ¹«°æÇÕ(ÙíÌæùê) ÀúÇØÁ¦(îÁúªð¥)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
OM obtuse mental; occipitomental; occupational medicine; ocular movement; oculomotor; Osborne Mendel [r...
OV oculovestibular; office visit; osteoid volume; outflow volume; ovalbumin; ovary; overventilation; ov...
ESI elastase-specific inhibitor; enzyme substrate inhibitor; epidural steroid injection
PTI pancreatic trypsin inhibitor; persistent tolerant infection; Pictorial Test of Intelligence; placent...
STI Scientific and Technical Information; serum trypsin inhibitor; soybean trypsin inhibitor; systolic t...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PI 1-protease inhibitor
PI 1-proteinase inhibitor
PIC 2-plasmin inhibitor plasmin complex
ACE-I ACE inhibitor
ACPI Acid cysteine proteinase inhibitor
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
mammary derived growth inhibitor Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells.
(18 Nov 1997)
mechanism-based inhibitor A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme.
Synonym: mechanism-based inhibitor.
(05 Mar 2000)
glucosidase inhibitor Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence.
(05 Mar 2000)
medication, ace-inhibitor Agents that inhibit ACE (angiotensin-converting enzyme), thereby acting as vasodilators (really as anti-vasoconstrictors), lightening the stress load on the heart.
(12 Dec 1998)
residual inhibitor A sound-generating device, worn in the ear, which inhibits or suppresses the sounds of tinnitus by masking, with a residual inhibitory effect when the device is turned off.
(05 Mar 2000)
respiratory inhibitor A compound that inhibits the respiratory chain.
Synonym: respiratory poison.
(05 Mar 2000)
cholinesterase inhibitor <pharmacology> These are substances which which act to inhibit acetylcholinesterase, the enzyme which breaks down acetylcholine and thus enhance and subsequently prevent transmission of nerve impulses from one nerve cell to another or to a muscle.
Examples include pyridostigmine, ambenonium and neostigmine.
(15 Jan 1998)
monoamine oxidase inhibitor <pharmacology> A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression.
Monoamine oxidase inhibitors are a group of antidepressant drugs that prevent the activity of the enzyme monoamine oxidase in the central nervous system (brain) thus affecting mood. The use of these medications is often restricted due to their severe side effects and drug (and food) interactions.
Examples include isocarboxazid, pargyline, selegiline, furazolidone and phenelzine.
Acronym: MAOI
(26 Mar 1998)
complement cytolysis inhibitor <protein> Vertebrate glycoprotein of uncertain function. Secreted as a 400 amino acid peptide, then cleaved to form two 200 amino acid peptides that are linked by a disulphide bridge.
Synonym: complement associated protein, complement cytolysis inhibitor, glycoprotein III.
(11 Jan 1998)
plasminogen activator inhibitor 1 <chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
plasminogen activator inhibitor 2 <chemical> Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
cyclooxygenase inhibitor <pharmacology> Compounds or agents that combine with cyclooxygenase (prostaglandin-endoperoxide synthase) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.
(08 Mar 2000)
protease inhibitor A drug that binds to and blocks HIV protease from working, thus preventing the production of new infectious viral articles.
(09 Oct 1997)
proteinase inhibitor inducing factor See: PIIF.
(18 Nov 1997)
protein c inhibitor <chemical> A member of the serpin family of proteins that is found in plasma and urine. It is dependent on heparin and able to inhibit activated protein c, thrombin, kallikrein, and other serine proteinases.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á